Medication info
Diovan Film-Coated Tablets 40mg (Valsartan)

Diovan Film-Coated Tablets 40mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›40mg / 1 tablet
Manufacturer / importer
Novartis Korea Ltd.
Appearance
Yellowish, round oval film-coated tablet
Packaging
28 tablets (14 tablets/PTP packaging X 2)
Approval status
Active

MFDS item code 200410067 · Notified 2004.01.07 · Insurance code 653600200

Summary

Main use
Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure
Who takes it
Adults · Children
Adult dose
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is needed. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose must not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, the dose should be increased according to the patient’s tolerability, with 40 mg, 80 mg, and 160 mg administered twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is needed for creatinine clearance of 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
6) Pediatric patients: The safety and efficacy of this medicine have not been established in children and adolescents younger than 18 years. 6. Pediatric patients: The safety and efficacy of this medicine have not been established in children and adolescents younger than 18 years.

Ingredients

Importer
Novartis Korea Ltd.

Efficacy & effects

Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • impaired left ventricular contractility
View approved original text

This medication is primarily used to control blood pressure in patients with essential hypertension. It is also helpful for patients with heart failure who exhibit intolerance to ACE inhibitors. It is suitable for heart failure patients classified as NYHA class II to IV. Additionally, it is used to reduce the risk of mortality in stable patients with left ventricular dysfunction or impaired contractile function following a myocardial infarction. This medication helps alleviate patient symptoms and enhance survival rates through blood pressure control and improvement of cardiac function. Therefore, it is used for the treatment of essential hypertension, heart failure, and the reduction of mortality risk after myocardial infarction.

How to take

Adult dose

(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is needed. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose must not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, the dose should be increased according to the patient’s tolerability, with 40 mg, 80 mg, and 160 mg administered twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is needed for creatinine clearance of 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

6) Pediatric patients: The safety and efficacy of this medicine have not been established in children and adolescents younger than 18 years. 6. Pediatric patients: The safety and efficacy of this medicine have not been established in children and adolescents younger than 18 years.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially during the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. It is safe to avoid this medication in women who are pregnant or breastfeeding. Patients with severe liver dysfunction or specific kidney diseases should not use this medication. Caution is advised for elderly patients, those with hyperkalemia, or patients with slight hepatic impairment, and dose adjustments may be necessary. Symptoms such as dizziness or a sudden drop in blood pressure may occur during treatment; thus, special care should be taken when starting the medication. When taken with other antihypertensive medications or diuretics, there may be an increase in serum potassium levels, necessitating regular blood tests. Since this medication can affect liver or kidney function, regular periodic tests should be conducted according to the physician’s instructions. Patients should be cautious of dizziness when driving or operating machinery. This medication is not recommended for use in children and adolescents due to unestablished safety and efficacy. In case of overdose, serious hypotension or decreased consciousness may occur, and immediate medical attention is required. Keep this medication out of the reach of children and do not transfer it to another container.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air and moisture. Additionally, it is important to keep it in a cool place below 30 degrees Celsius in order to maintain the drug's efficacy.

Appearance and packaging

Appearance

Yellowish, round oval film-coated tablet

Package unit

28 tablets (14 tablets/PTP packaging X 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.